Senate sends Biden military bill that would lift Covid vaccine mandate for troops and authorize more Ukraine funding

Senate sends Biden military bill that would lift Covid vaccine mandate for troops and authorize more Ukraine funding


Preventative Medicine Services NCOIC Sergeant First Class Demetrius Roberson administers a COVID-19 vaccine to a soldier on September 9, 2021 in Fort Knox, Kentucky.

Jon Cherry | Getty Images

The Senate passed a massive military policy bill Thursday that would direct the Defense Department to lift a Covid vaccination mandate for service members and authorize $858 billion in defense spending.

The National Defense Authorization Act, the annual bill that authorizes Pentagon spending and policies, cleared the Senate in an 83-11 vote. Five Republicans and six Democrats opposed the measure.

It passed the House in a 350-80 vote last week.

The legislation now heads to President Joe Biden’s desk for his signature.

The bipartisan bill would authorize funding for Taiwan and Ukraine and a 4.6% pay increase for troops. It also would do away with the military vaccination mandate, a Republican priority. Democratic leaders allowed the new Covid language to ensure timely passage of the bill.

A GOP-backed amendment that pushed for scrapping the vaccination mandate immediately instead of waiting several weeks failed to meet the 60-vote threshold needed for adoption in the Senate.

A separate amendment, offered by Sen. Joe Manchin, D-W.Va., sought to overhaul the process to authorize energy and infrastructure projects, known as permitting reform, in the authorization bill. It also fell short of the 60-vote threshold.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More